Cannabis Price Compression: Why Prices Keep Falling and What Fixes It

Photo by Ihsan Adityawarman via Pexels.

Something broke in the numbers this year that hadn't broken before. U.S. cannabis revenue fell in 2025 even though people bought more product than ever, according to figures from Headset and Whitney Economics. That's not a demand problem. Americans are buying more cannabis by weight and by unit than they were a year earlier. They're just paying a lot less for it, and the industry's revenue line is bleeding out as a result.

The Cannabis Spot Index tells the same story in a single chart. It hit a record low of $888 a pound in January 2025, clawed back about 15% over the following months, and then gave almost all of it up again, sliding 6.8% year-to-date to land at $1,015 a pound as of April 3, 2026. LeafLink's 2026 Wholesale Pricing Guide, pulling from more than 400,000 SKUs across 18 states, shows the damage isn't evenly spread: cartridges are down 12% year-over-year, pre-rolls down 10.3%, while edibles have barely budged. And all of this is landing right as medical cannabis operators just got a tax break that recreational operators — the ones actually hemorrhaging revenue — can't touch. That mismatch is the real story here.

The Numbers Behind the Crash

In 2026, wholesale prices are projected to fall year-over-year across most cannabis categories, led by steep declines in cartridges (-12%) and pre-rolls (-10.3%), while edibles buck the trend with a slight 1.7% price increase.

Start with the headline figure, because it's the one that should worry anyone with capital in this industry: cannabis revenue in the United States declined in 2025 for the first time since state-legal markets began scaling up, per data compiled by Headset and Whitney Economics. Unit sales and volume both rose. Revenue still fell. That combination only happens when average selling prices are dropping faster than consumption is growing, and that's exactly what's showing up in wholesale data nationwide.

The Cannabis Spot Index is a useful proxy for where wholesale flower pricing sits nationally, and its recent path looks like a dead-cat bounce. It bottomed at $888 per pound in January 2025 — a record low at the time — then recovered about 15% over the following months as some markets tightened up. That recovery didn't hold. By April 3, 2026, the index had fallen 6.8% year-to-date to $1,015 per pound, erasing a big chunk of the gains and confirming that last year's bounce was a blip, not a turnaround.

LeafLink's May 2026 Wholesale Pricing Guide breaks the pain down by category, and the spread is telling. Cartridges are down 12.0% year-over-year, pre-rolls down 10.3%, concentrates down 7.5%, and flower down 5.4%. Edibles are the outlier, up 1.7%. That's not a rounding error — it's a signal. Categories that compete heavily on potency numbers and commoditized hardware are getting crushed, while a category built around branded formulations, dosing consistency, and flavor differentiation is holding its price. If you're building a brand strategy in 2026, that's the chart to study.

Michigan and New York: Two Different Diseases

Photo by Erik Mclean via Pexels.

Michigan and New York are both dealing with falling average prices, but they're not sick with the same disease, and treating them the same way would be a mistake. Michigan dispensaries reported $226.8 million in sales in January 2026, down 8.3% from the same month a year earlier. The state's unlimited-license structure has let cultivation capacity run far ahead of what the market can absorb, and that oversupply is the primary force pushing wholesale and retail prices down month after month.

Michigan also just layered a new 24% wholesale cannabis tax on top of that, effective January 1, 2026, part of Governor Whitmer's $81 billion state budget. The Michigan Cannabis Industry Association has filed suit calling the tax unconstitutional, and that fight will play out in court over the coming months. But it's worth being precise about cause and effect: most analysts point to oversupply, not the new tax, as the dominant driver of Michigan's price collapse. The tax makes a bad situation worse for margins, but it didn't create the glut of flower sitting in vaults across the state.

New York is almost the mirror image. Average item price there fell to $31.29 in February 2026, down from $35.41 a year earlier — a real decline, but one that still leaves New York among the most expensive legal markets in the country. The reasons are structural rather than about oversupply: the state's licensed retail buildout is still young, dispensary density per capita remains low compared to mature markets like Colorado or Michigan, and an entrenched illicit market continues to undercut legal storefronts on price. New York's prices are falling toward sustainability. Michigan's are falling toward crisis. Check your own state's licensing pace before assuming either pattern applies where you operate.

Rescheduling Won't Save Recreational Markets

Photo by Efrem Efre via Pexels.

The DOJ's final order on April 22-23, 2026 moved state-licensed medical cannabis to Schedule III, and for medical operators the effect is immediate and real: the punishing IRC §280E tax burden, which barred cannabis businesses from deducting ordinary business expenses, is gone retroactive to January 1, 2026. That's meaningful money flowing back to medical-only operators in states that still maintain a separate medical program.

Here's the catch that matters for this whole pricing crisis: adult-use cannabis remains Schedule I. Nothing changed for recreational operators. And recreational markets are precisely where most of the price compression covered above is happening — Michigan's unlimited-license glut, the vape and pre-roll categories getting hammered in LeafLink's data, the broader revenue decline Headset and Whitney Economics flagged for 2025. Rescheduling medical cannabis does nothing to relieve the segment of the industry bleeding out the fastest.

There's a broader process underway that could eventually reach recreational cannabis. A June 29, 2026 administrative hearing is building the record toward a possible full rescheduling of cannabis across all use categories, and a final rule could theoretically arrive as soon as late 2026. Litigation from multiple directions could easily push that timeline out further, and nobody should plan a business model around a specific date.

Even if full rescheduling happens, it doesn't touch the other structural problem: interstate commerce is still illegal under federal law. Michigan and Oregon can't ship their oversupply to a tight, high-priced market like New York no matter what schedule cannabis sits on domestically. That single restriction is arguably doing more to keep this crisis contained state by state than any tax code provision. Confirm current federal and state law directly before making any business decisions based on rescheduling timelines.

Is This a Failure or Just the Market Working?

Photo by Mark Stebnicki via Pexels.

Not everyone treats falling prices as an emergency. A May 2026 report from Whitney Economics and the Global Cannabis Network Consortium argues that price compression is a predictable phase of legalization's growth curve, not evidence that regulators or operators are failing. Every commodity market that scales production quickly runs through a period where supply overshoots demand and prices fall hard before settling into a more rational equilibrium.

The report's sharper argument is that regulators and operators keep making the same forecasting mistake: underestimating how fast commoditization happens once license counts climb past a certain threshold. A market can look tight and profitable for two or three years, then flip into oversupply within a single licensing cycle once enough new cultivation capacity comes online at once. Michigan's trajectory is the textbook example.

The report leans on comparisons to established agricultural commodities like corn and coffee, both of which saw brutal early-stage price crashes after periods of rapid production scale-up, followed eventually by consolidation and more disciplined supply management. Cannabis, in this framing, isn't behaving abnormally — it's behaving like any newly commoditized crop finding its floor.

Why does this framing matter beyond academic interest? Because it changes what the correct policy response looks like. If this is a market failure, the instinct is emergency relief — tax cuts, price floors, subsidies. If it's a predictable S-curve phase, the fix is about pacing: slowing license issuance, encouraging consolidation, and letting weaker operators exit rather than propping up an oversupplied field. Those are very different policy conversations, and states are currently having both at once.

What Operators and Regulators Are Actually Trying

Photo by Richard T via Pexels.

Regulators do control one lever directly, and some are finally pulling it: the pace of license issuance. States watching Michigan's collapse in real time are reconsidering unlimited-license models, and a few are quietly slowing new approvals or capping cultivation license classes rather than waiting for a full-blown oversupply crisis to force their hand.

On the operator side, consolidation is accelerating. Smaller cultivators without deep balance sheets can't survive for long on compressed wholesale margins, and mergers and acquisitions activity is picking up as stronger operators buy distressed assets rather than build new capacity from scratch. Expect that trend to keep running through 2026 and into 2027 in the hardest-hit states.

Vertical integration is proving to be one of the more durable survival strategies. Multi-state operators that control cultivation, processing, and retail can absorb a wholesale price crash better than standalone cultivators because they capture margin further down the chain at the dispensary counter, even when the wholesale price of their own flower is falling.

• Brand differentiation and proprietary genetics are shifting from marketing extras to genuine survival tools, echoing the edibles category's relative price stability
• Retail-level customer loyalty and consistent formulation matter more as commoditized flower and cartridges race toward a price floor
• Operators without a recognizable brand or unique cultivar increasingly compete on price alone, the least sustainable position in a compressed market

Economists still point to interstate commerce as the eventual structural fix, letting oversupplied states like Michigan or Oregon sell into undersupplied ones like New York. Executives are less enthusiastic, warning that opening interstate trade without guardrails could trigger a national race to the bottom, flooding every state with the cheapest available flower and dragging prices down everywhere at once rather than balancing the market out.

None of this resolves with a single policy fix. Medical rescheduling helps the operators lucky enough to hold medical licenses in states that still separate medical from recreational programs, but it does nothing for the adult-use side of the business where the actual revenue decline and category-level price crashes are concentrated. Treating rescheduling as the industry's rescue plan misreads what's actually happening in the data.

The states pulling ahead of this crisis are the ones treating licensing discipline and consolidation as active policy tools rather than letting an unlimited-license market crash and hoping it rebuilds itself on its own timeline. Michigan is currently running the experiment on what happens when you don't do that. New York is running a slower, more controlled experiment in the opposite direction, and its prices, while still high, are moving toward sustainability rather than collapse.

If you're operating in this space or investing in it, the practical move is to stop watching national averages and start watching your own state's licensing pace, tax structure, and litigation calendar, since outcomes are diverging sharply by jurisdiction rather than converging toward one national story. Cannabis law and tax treatment both vary significantly by state and are shifting quickly at the federal level, so confirm current local rules directly before making any decisions based on the figures here.